Trials / Not Yet Recruiting
Not Yet RecruitingNCT07415031
A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies
Solid Tumor Study for Long Term Treatment of Cancer Patients Who Have Participated in BMS Parent Studies Investigating Adagrasib (BMS-986503)
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 170 (estimated)
- Sponsor
- Mirati Therapeutics Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-label, solid tumor, continuation, rollover trial which enrolls participants from ongoing BMS parent studies that evaluated adagrasib (MRTX849, BMS-986503) either as monotherapy or in combination with other cancer therapies in patients with non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and other advanced solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Adagrasib | Specified dose on specified days |
| DRUG | Pembrolizumab | Specified dose on specified days |
| DRUG | Cetuximab | Specified dose on specified days |
| DRUG | Pemetrexed | Specified dose on specified days |
| DRUG | Docetaxel | Specified dose on specified days |
| DRUG | Irinotecan | Specified dose on specified days |
| DRUG | Leucovorin | Specified dose on specified days |
| DRUG | Oxaliplatin | Specified dose on specified days |
| DRUG | Fluorouracil | Specified dose on specified days |
Timeline
- Start date
- 2026-05-16
- Primary completion
- 2028-02-16
- Completion
- 2028-02-16
- First posted
- 2026-02-17
- Last updated
- 2026-04-08
Locations
30 sites across 6 countries: United States, Canada, Germany, Portugal, Romania, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07415031. Inclusion in this directory is not an endorsement.